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REPLY
We thank Dr. Connolly and colleagues for their interest in our
editorial comment (1). They provide a snapshot of their experience
performing percutaneous coronary intervention (PCI) at a hospital
without cardiac surgery backup. Approximately 40% of their cases
were elective, 60% were in “unstable” patients, and about 10% were
primary PCIs. They report five cases (0.6%) requiring urgent
coronary artery bypass surgery (UCABG) and four mortalities
(0.5%). These all occurred in the unstable cohort, with no deaths
or UCABG in elective patients. It is not stated whether any of the
deaths occurred in the five cases that required UCABG, but we
know mortality is increased if UCABG is necessary (2). We
understand that full disclosure about complications is difficult
given the constraints of a Letter to the Editor, but the question
could be asked: has their experience led them to change their
practice pattern? Because all of their mortalities and UCABG
occurred in unstable patients, are unstable patients now being
referred to the surgical center just a few miles away?
In addition, if one accepts the report of Lotfi et al. (3), one out
of four patients requiring UCABG would be placed at increased
risk of harm if delays to surgery were encountered, and about 70%
would require stabilization with a balloon pump. Dr. Connolly and
colleagues state there was “no delay in surgical transfer,” but the
actual, time required for transfer is not provided. Perhaps these
same patients would have died or needed UCABG even if they had
PCI at the surgical center. Because the risk of a severe complica-
tion from PCI is now very low, even centers with on-site cardiac
surgery rarely hold a surgical suite in a state of immediate
readiness, but rather depend on the fact that an operating room
(OR) and surgeon will be available on short notice should a
complication arise. Perhaps in their setting this would result in a
similar time delay; however, there is still the issue of moving an
unstable patient, often with a balloon pump, from the catheter-
ization laboratory to an ambulance, traveling to another hospital,
unloading the patient and transporting him or her to the OR. We
acknowledge this can be done, but is this truly in the best interest
of the patient when a hospital with on-site surgery is just a few
miles away?
Perhaps in the future, PCI will be perfected to the point that the
need for UCABG will be zero. Unfortunately, even in the best PCI
centers in the world, we are not yet at that point. Should that time
come, however, it would be appropriate to perform PCI at centers
without on-site surgery. Until then, this argument is not about
monopolizing care to surgical centers, but performing PCI under
the safest possible conditions one can provide for patients.
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REPLY
Drs. Gubner and Rowe express concern about the conclusions and
implications of our study (1) and the accompanying editorial
comment (2). In regards to transfer delays, data from experienced
centers have consistently shown that patients who require urgent
coronary artery bypass grafting (UCABG) after failed percutane-
ous coronary intervention (PCI) have dramatically longer times to
surgery in hospitals without versus with on-site surgical availability
(359  406 min vs. 170  205 min; p  0.0001) (3). In this large
series, even though the number of patients with three-vessel
disease was significantly less in the group without on-site surgery
(9% vs. 22%; p  0.05), the mortality rate was not lower—thus
raising concerns that delays to surgery may have been a detrimental
factor. Although all of the UCABG patients in our cohort who
had at least one of the prespecified criteria were rushed to surgery
within 2 h, we did not suggest that this time frame should be
mandated as the “standard of excellence.” However, it would be
reasonable to suggest that rapid treatment of these unstable
UCABG patients is important and more likely to be accomplished
at centers with on-site surgical availability. Also, there are other
incentives (i.e., financial, access) to establishing new elective
angioplasty programs without on-site cardiac surgery, and our
study’s main objective was to add information on the potential risk
of doing so. We believe it is in the best interest of patients and the
cardiology community to have well-delineated strategies to mon-
itor the expansion and performance of such centers in a carefully
transparent fashion.
We appreciate the comments of Dr. Connolly and colleagues
detailing their experience with angioplasty without surgical
backup. The 0.6% UCABG rate is similar to the rate in our report,
but with only 338 elective cases in their cohort, it is difficult to
make any generalizable statements about the safety of elective
angioplasty without surgical backup. In our report, 15 (0.5%) of
the 3,039 patients who had elective angioplasty required UCABG.
One-third of these elective patients who required UCABG met
our prespecified criteria for increased harm attributable to delays of
surgery.
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Cardiac Resynchronization
Therapy in Patients With Narrow QRS
We read with great interest the report by Achilli et al. (1) on
cardiac resynchronization therapy (CRT) in patients with heart
failure (HF) and narrow QRS: the clinical implication of those
data is huge in light of the rapidly expanding indications for CRT.
Achilli et al. (1) described the “long-term” efficacy of CRT in 52
patients (all preselected by echocardiographic recognition of inter-
and intraventricular dyssynchrony) affected by HF, 14 of them
with a QRS 120 ms. Positive results were obtained both from a
clinical and echocardiographic point of view.
The fact that the mean follow-up was 565 days, but that the
“clinical and echocardiographic results” refer to the six-month
follow-up, could be a bit confusing. This may be misleading, and
no doubt the definition of “mid-term” rather than “long-term”
would be more appropriate in describing the follow-up by Achilli
et al. (1).
Our larger experience (158 patients, mean follow-up 1 year) (2),
published just a year before Achilli et al. (1) study (and probably
overlooked by the investigators) also confirms positive results of
CRT in patients with narrow QRS. Based purely on basal QRS
duration, without preselection by any echocardiographic parame-
ter, our patients were defined as wide QRS (150 ms, 128
patients) and narrow QRS (150 ms, 30 patients, 13 with QRS
120 ms, a number comparable to the Achilli et al. [1] narrow
QRS cohort). Our data confirm that, in both groups, CRT
significantly improved clinical and echocardiographic parameters;
in our series these good results were sustained for at least one year.
The most relevant difference between Achilli et al’s. (1) and our
population concerns the mortality rate in the narrow QRS group;
in fact, the 21.4% reported by Achilli et al. (1) in patients with
narrow QRS strongly contrasted with no deaths in our series. In
addition, the mortality rate reported by the investigators was
similar in patients with both narrow and wide QRS duration,
being substantially higher than other reported series.
Finally, we agree that echocardiographic indicators of dyssyn-
chrony can be useful; nonetheless, our data on patients with narrow
QRS have clearly demonstrated that the use of pure “clinical”
selection criteria (i.e., drug refractoriness, severe HF, low ejection
fraction, large diameters) has permitted us to identify patients who
can substantially benefit from CRT in the long term.
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REPLY
We appreciate the interest of Dr. Gasparini and colleagues in our
report (1) and respond to their specific points as follows. First, as
regards our follow-up, we are of the opinion that the definition of
“long-term” is correct considering a mean observation period for
our patient population of 546 days, but clinical and echocardio-
graphic data were collected at 6 months as this reflected the
minimum follow-up for all patients and we believed that this
guaranteed a homogeneous data evaluation. Nevertheless, the
latter definition obviously reflects a “mid-term” follow-up.
Second, we agree that the data published by Gasparini et al. (2)
concur with ours in underscoring the benefit of cardiac resynchro-
nization therapy (CRT) in patients with heart failure and narrow
QRS. However, the definition of a “narrow” QRS is substantially
different in the two studies (110  10 ms vs. 133  15 ms), thus
making the confrontation between patient populations inappropri-
ate as regards the electrical asynchrony profile. Moreover, we
acknowledge with pleasure that 13 patients in the Gasparini et al.
(2) series had a QRS duration 120 ms, but this issue was not
cited in the original report.
The major difference between the two populations is in the
criteria used for the selection of patients. We required the presence
of inter- and intraventricular asynchrony documented by echocar-
diography, whereas the Gasparini et al. (2) patients were selected
solely on the basis of clinical features.
Third, the high mortality rate of our patients might be due to a
disproportionate percentage of New York Heart Association
(NYHA) functional class IV (40%) patients with respect to
previous studies and the absence of functional class II patients in
our study; this is because we had decided, at least in the initial
phase of our experience, to reserve CRT for very ill patients.
Conversely, the subgroup with a narrow QRS from the Gasparini
et al. (2) series included 40% of NYHA functional class II patients.
2096 Correspondence JACC Vol. 44, No. 10, 2004
November 16, 2004:2087–98
